John Poulos Group Vice President, Global Pharmaceutical Licensing and New Business Development Abbott
	Mark Miller Senior Director, Corporate Business Development Lilly
	Jules Musing Vice President Licensing & Development Johnson & Johnson
	Scott Kennedy, PhD Executive Director, Worldwide Exploratory Science and Technology, External Research Network, East Region and Canada Pfizer

The complexity of large pharmaceutical organizations, and the knowledge of who really is a decision maker and who is not, can be the determining factor in what sends a biotechnology company into the woods. Small biotech companies can not lose time identifying the decision makers within potential partners and how these players are making decisions about why to take on the development of one compound and not the development of another compound. A big concern that small companies have is how are the industry giants making decisions regarding their product portfolio? This candid conversation will bring together players from pharma with the goal of:

• Identifying key contacts within large pharma bureaucracy
• Explaining what big pharma players looking for and how to discover future opportunities
• Understanding the most effective methods of delivering your message to large pharma

Linda Egger, PhD Director, Scientific Liaison, Oncology, External Scientific Affairs Merck & Co., Inc.

This presentation will discuss Merck’s R&D and Licensing Strategies with examples of recent Oncology partnerships from 2007 and 2008. “Merck's scientific licensing provides a unique opportunity to partner with other companies who share their commitment to top-notch science and passion for discovering and developing breakthrough products. Together, we can combine our strengths to deliver novel therapies that will transform human healthcare."

	Lyndal Hesterberg, Ph.D. President and CEO BaroFold
	Ira Weiss Vice President of Finance and Operations BioDtech, Inc.
	David Kalergis CEO Diffusion Pharmaceuticals

Uncovering unmet medical needs is on the tip of everyone’s tongues. This panel presentation will examine the successes and setbacks encountered through working with universities, and the ability to increase your R&D efforts through this type of collaboration. This panel discussion will address:

• Understanding how Biotech companies stay connected with universities and medical schools.
• Identifying how you can form alliances which keep ideas speeding out of universities and into the marketplace.
• Discovering how to locate Universities interested in working with your company and the potential outcomes for sustaining your pipeline.

David Wurtman Vice President of Corporate Development NexBio

Sometimes you don’t need to look any further than your own backyard to provide your company with its next big idea, however, you may have to dig a little deeper. This presentation will indulge in the many outlets for drug recovery as well as discovery, maximizing the revenue potential on all accounts.

• Thinking broadly about all of your company's assets.
• Progressing business development efforts within your current pipeline.
• Capitalizing on the revenue potential of existing products.
• Creating stability for your company in the marketplace, whether you're marketing a product or the entire company.

Joseph S. Dillon Senior Vice President, Corporate Development Services MattsonJack

As business development professionals, we must have global vision to embrace drivers of value and create innovative deal structures that capture the full global potential of opportunities. This session will focus on specific issues encountered when assessing commercial value in today’s fiercely competitive licensing and M&A environment. Each region of the world has its own uniqueness that we must understand. Treatment protocol, patient behavior, epidemiology, competitive environment, regulatory, partner behaviors and a host of other factors are likely to vary significantly country to country. Some factors transcend borders, while others are country specific. International themes flavor even single country license deals. This session includes reference to specific examples and case studies as we work through the building (or stumbling) blocks of global deal assessment.

	Deborah Barbara VP Business Development and Licensing Ore Pharmaceuticals
	Eric De La Fortelle Global Head, External Research and Technology Roche

Gene Logic's Drug Repositioning Program seeks to find alternative indications for drug candidates with good safety records that have been de-prioritized or discontinued in clinical trials. The program offers pharmaceutical partners a novel approach to bolster their latestage pipelines with safe, high-quality drug candidates that originated from their own R&D efforts. This case study is focused on the successful collaboration between Gene Logic and Roche to aid in:

• Identifying the goals and values specific to large pharma in order to approach them with an appealing opportunity.
• Developing the terms of the collaboration to realize the full potential of revitalized pharma assets.
• Working together to support buy-in to the collaboration

Pavan Handa Vice President of Business Development Noven Pharmaceuticals

The pharmaceutical industry is facing a myriad of challenges that range from declining R&D productivity to generic competition. At the same time, industry biases are preventing us from timely utilization of drug delivery options to unleash brand equity. Innovations in drug delivery technologies have resulted in breathing new life into mature brands or have created blockbuster products from well-established compounds. Using new drug delivery formulations to extend product life is a profitable portfolio development strategy. This presentation will expose your biases and present several case studies illustrating the power of innovative drug delivery technologies while:

• Understanding how industry biases are preventing us from exploiting brand equity
• Exploring how novel drug delivery methods extend patent life of your products
• Discussing the value of collaborating with drug delivery companies to sustaining the life of your pipeline
• Presenting case studies on how new drug delivery technologies have created blockbuster brands from old compounds or revived declining brands

BioNetwork East 2008 is offering even more intimate networking and discussion opportunities exploring the hurdles and solutions being encountered by others in the industry. Take this opportunity to meet with your colleagues to discuss common challenges and explore additional collaboration possibilities. Roundtable moderators and topics will rotate, giving you the chance to attend numerous sessions. Roundtables Include:

• Protecting patents
• Structuring deals that recognize the potential for multiple Indications
• Research tools to assess market potential
• Leveraging alliance management into licensing
• Leveraging alliance management into licensing

*Additional roundtables available upon request. Please email bionetwork@wbresearch to request a roundtable.